Center for Cancer Research
National Cancer Institute
United States of America
Dr. Goncalves received her M.D. from the Universidade Federal de Minas Gerais, UFMG in Brazil. She trained in medical oncology at the Brazilian National Cancer Institute, Rio de Janeiro. She completed a fellowship in early drug development at Wayne State University, Detroit, MI. She completed her medical oncology fellowship at the National Cancer Institute and later joined the HIV and AIDS Malignancy Branch as a Staff Clinician. She has received grants from the American Society of Clinical Oncology and has been involved in several oncology phase 1 clinical trials and a phase 2 clinical trial on vorinostat in patients with adenoid cystic carcinoma.
1) HIV/AIDS-associated malignancies, 2) early drug development, 3) virally associated malignancies, 4) head and neck cancer, 5) salivary gland cancer, 6) lung cancer
Goncalves PH, High F, Juniewicz P, Shackleton G, Li J, Boerner S, LoRusso PM. Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies. Investigational new drugs. 2008 Aug 1;26(4):347-54.
LoRusso PM, Goncalves PH, Casetta L, Carter JA, Litwiler K, Roseberry D, Rush S, Schreiber J, Simmons HM, Ptaszynski M, Sausville EA. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Investigational new drugs. 2015 Apr 1;33(2):440-9.
Kranick SM, Goncalves PH, Stetler-Stevenson M, Aleman K, Polizzotto MN, Little RF, Yarchoan R, Uldrick TS. Paradoxical central nervous system immune reconstitution syndrome in acquired immunodeficiency syndrome-related primary central nervous system lymphoma. haematologica. 2015 Jan 1;100(1):e21-4.